Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Nakajima Y, Tachimori H, Miyawaki Y, et al. A survey of the clinical outcomes of cervical esophageal carcinoma surgery focusing on the presence or absence of laryngectomy using the National Clinical Database in Japan. Esophagus. 2022;19:569–75.
2. Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020;38:2677–94.
3. Kato K, Ito Y, Daiko H, et al. A randomized controlled Phase III trial comparing doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: the JCOG1109 NExT study. Lancet. (in press).
4. Kubo Y, Makino T, Yamasaki M, et al. Three-course neoadjuvant chemotherapy associated with unfavorable survival of non-responders to the first two courses for locally advanced esophageal cancer. Ann Surg Oncol. 2023;30:5899–907.
5. Kubo Y, Nozaki R, Igaue S, et al. Neoadjuvant chemotherapy improves feasibility of larynx preservation and prognosis for resectable locally advanced cervical esophageal cancer. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15432-4.